SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ralf Reilmann, Marie-Laure Rouzade-Dominguez, Carsten Saft, Sigurd D. Süssmuth, Josef Priller, Anne Rosser, Hugh Rickards, Ludger Schöls, Nicole Pezous, Fabrizio Gasparini, Donald Johns, Georg Bernhard Landwehrmeyer, Baltazar Gomez-Mancilla, A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease, Movement Disorders, 2015, 30, 3
  2. 2
    Vincent A. Jourdain, Nicolas Morin, Laurent Grégoire, Marc Morissette, Thérèse Di Paolo, Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy, Journal of Neurosurgery, 2015, 1

    CrossRef

  3. 3
    Nicolas Morin, Marc Morissette, Laurent Grégoire, Thérèse Di Paolo, Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 27

    CrossRef

  4. 4
    Lufei Shan, Oscar Diaz, Yajun Zhang, Bruce Ladenheim, Jean-Lud Cadet, Yung-Hsiao Chiang, Lars Olson, Barry J. Hoffer, Cristina M. Bäckman, l-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or l-Dopa history, Brain Research, 2015, 1618, 261

    CrossRef

  5. 5
    Thierry Wendling, Kayode Ogungbenro, Etienne Pigeolet, Swati Dumitras, Ralph Woessner, Leon Aarons, Model-Based Evaluation of the Impact of Formulation and Food Intake on the Complex Oral Absorption of Mavoglurant in Healthy Subjects, Pharmaceutical Research, 2015, 32, 5, 1764

    CrossRef

  6. 6
    Flavia Niccolini, Lorenzo Rocchi, Marios Politis, Molecular imaging of levodopa-induced dyskinesias, Cellular and Molecular Life Sciences, 2015, 72, 11, 2107

    CrossRef

  7. 7
    Cornelis J Van der Schyf, Rational drug discovery design approaches for treating Parkinson’s disease, Expert Opinion on Drug Discovery, 2015, 10, 7, 713

    CrossRef

  8. 8
    Andrea Ferrigno, Mariapia Vairetti, Giulia Ambrosi, Vittoria Rizzo, Plinio Richelmi, Fabio Blandini, Marie-Therese Fuzzati-Armentero, Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats, Clinical and Experimental Pharmacology and Physiology, 2015, 42, 6
  9. 9
    Nikhil M. Urs, Simone Bido, Sean M. Peterson, Tanya L. Daigle, Caroline E. Bass, Raul R. Gainetdinov, Erwan Bezard, Marc G. Caron, Targeting β-arrestin2 in the treatment of l-DOPA–induced dyskinesia in Parkinson’s disease, Proceedings of the National Academy of Sciences, 2015, 112, 19, E2517

    CrossRef

  10. 10
    Manuela Pilleri, Angelo Antonini, Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease, Expert Opinion on Drug Safety, 2015, 14, 2, 281

    CrossRef

  11. 11
    Peter Jenner, Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future, Translational Neurodegeneration, 2015, 4, 1, 3

    CrossRef

  12. 12
    Wai Kin D. Ko, Elsa Pioli, Qin Li, Steve McGuire, Audrey Dufour, Todd B. Sherer, Erwan Bezard, Maurizio F. Facheris, Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease, Movement Disorders, 2014, 29, 6
  13. 13
    Wendy R. Galpern, Christopher S. Coffey, Alberto Albanese, Ken Cheung, Cynthia L. Comella, Dixie J. Ecklund, Stanley Fahn, Joseph Jankovic, Karl Kieburtz, Anthony E. Lang, Michael P. McDermott, Jeremy M. Shefner, Jan K. Teller, John L. P. Thompson, Sharon D. Yeatts, H. A. Jinnah, Designing Clinical Trials for Dystonia, Neurotherapeutics, 2014, 11, 1, 117

    CrossRef

  14. 14
    Amaal Al Dakheel, Isabelle Beaulieu-Boire, Susan H Fox, Emerging drugs for levodopa-induced dyskinesia, Expert Opinion on Emerging Drugs, 2014, 19, 3, 415

    CrossRef

  15. 15
    F.I. Tarazi, Z.T. Sahli, M. Wolny, S.A. Mousa, Emerging therapies for Parkinson's disease: From bench to bedside, Pharmacology & Therapeutics, 2014, 144, 2, 123

    CrossRef

  16. 16
    M. Angela Cenci, Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease, Biochemical Society Transactions, 2014, 42, 2, 600

    CrossRef

  17. 17
    Nicolas Morin, Vincent A. Jourdain, Marc Morissette, Laurent Grégoire, Thérèse Di Paolo, Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys, Neuropharmacology, 2014, 79, 688

    CrossRef

  18. 18
    Dmitry Petrov, Ignacio Pedros, Maria Luisa de Lemos, Mercè Pallàs, Anna Maria Canudas, Alberto Lazarowski, Carlos Beas-Zarate, Carme Auladell, Jaume Folch, Antoni Camins, Mavoglurant as a treatment for Parkinson’s disease, Expert Opinion on Investigational Drugs, 2014, 23, 8, 1165

    CrossRef

  19. 19
    G. Sciamanna, G. Ponterio, A. Tassone, M. Maltese, G. Madeo, G. Martella, S. Poli, T. Schirinzi, P. Bonsi, A. Pisani, Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia, Neuropharmacology, 2014, 85, 440

    CrossRef

  20. 20
    Anne-Catherine Vijverman, Susan H Fox, New treatments for the motor symptoms of Parkinson’s disease, Expert Review of Clinical Pharmacology, 2014, 7, 6, 761

    CrossRef

  21. 21
    Eva Schaeffer, Andrea Pilotto, Daniela Berg, Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease, CNS Drugs, 2014, 28, 12, 1155

    CrossRef

  22. 22
    Nicolas Morin, Thérèse Di Paolo, Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates, Frontiers in Neurology, 2014, 5,

    CrossRef

  23. 23
    Tanja Babic, R. Alberto Travagli, Role of metabotropic glutamate receptors in the regulation of pancreatic functions, Biochemical Pharmacology, 2014, 87, 4, 535

    CrossRef

  24. 24
    Barbara Picconi, Paolo Calabresi, Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?, Movement Disorders, 2014, 29, 6
  25. 25
    Fabrizio Stocchi, Therapy for Parkinson’s Disease: What is in the Pipeline?, Neurotherapeutics, 2014, 11, 1, 24

    CrossRef

  26. 26
    Juan C. Giugni, Michael S. Okun, Treatment of advanced Parkinsonʼs disease, Current Opinion in Neurology, 2014, 27, 4, 450

    CrossRef

  27. 27
    Albert Y. Hung, Michael A. Schwarzschild, Treatment of Parkinson’s Disease: What’s in the Non-dopaminergic Pipeline?, Neurotherapeutics, 2014, 11, 1, 34

    CrossRef

  28. 28
    Olivier Rascol, Susan Fox, Fabrizio Gasparini, Christopher Kenney, Thérèse Di Paolo, Baltazar Gomez-Mancilla, Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias, Parkinsonism & Related Disorders, 2014, 20, 9, 947

    CrossRef

  29. 29
    David Devos, Caroline Moreau, Kathy Dujardin, Ioav Cabantchik, Luc Defebvre, Regis Bordet, New Pharmacological Options for Treating Advanced Parkinson’s Disease, Clinical Therapeutics, 2013, 35, 10, 1640

    CrossRef